GLENDALE, ARIZ.—Arizona is a microcosm of America’s challenges in reconciling the rheumatology workforce to growing patient demand, as quantified in the ACR’s Workforce Study of 2015.1 So it was timely this year for the Phoenix Rheumatology Association to sponsor its 1st Annual Strategic Training for Rheumatology Advanced Practice Clinicians Symposium. (Note: Advanced practice clinicians [APCs]…
Save the date for the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Connect with your colleagues for an unmatched educational experience featuring exceptional sessions by leading rheumatology experts. The ACR/ARHP Annual Meeting is your gateway to global rheumatology education. With more than 450 sessions—including The Great Debate—the meeting provides boundless opportunities for professional development,…
With more than 450 sessions, the 2018 ACR/ARHP Annual Meeting, is your gateway to global rheumatology education. Here is a preview of a few sessions attendees can look forward to…
Systemic lupus erythematous (SLE) is a chronic inflammatory disease that predominantly affects women and can involve virtually any organ. The authors of this study analyzed secular trends and population characteristics associated with SLE mortality. Objective: Mortality statistics from the Centers for Disease Control and Prevention (CDC) are used for planning healthcare policy and allocating resources….
Preventing adverse outcomes in individuals who have rheumatic diseases is a daily goal for rheumatologists. For example, rheumatologists prescribe medications and perform screening to prevent erosions in rheumatoid arthritis (RA), renal failure in systemic lupus erythematosus and flares across all diseases. Many of these actions are classified as secondary or tertiary prevention, because individuals have…
The ACR’s ability to address the big picture of rheumatologic care while focusing on individual practice and patient needs is one of the many things that attracted Luke Barré, MD, MPH, to the College early in his career. With training in both preventive medicine and rheumatology, Dr. Barré believes combined global and local views are…
Could your lupus patients benefit from limiting exposure to chemicals at home and in the medical environment? It’s a strong possibility, according to the preliminary findings of a research team investigating DNA methylation disruption in patients with SLE…
When Paul Sufka, MD, a rheumatologist with HealthPartners Medical Group and Regions Hospital in St. Paul, Minn., wants to connect with his colleagues or keep abreast of the latest rheumatology journal articles, he turns to Twitter. Dr. Sufka is one of many rheumatologists who have found effective ways to incorporate social media into their medical…
New data indicate that outreach is working: the interest of young medical professionals in rheumatology is growing. But as this interest grows, so will demand for rheumatology positions and funding for fellowships. The ACR has a plan to address these needs…
Various drugs are known to cause musculoskeletal symptoms, such as arthralgias, myalgias, drug-induced lupus and serum sickness.1 In the rheumatology world, the most commonly recognized drugs that can cause musculoskeletal symptoms are hydralazine, minocycline, fluoroquinolones and, recently, the dipeptidyl peptidase 4 (DPP-4) inhibitor class of medications. Although beta blockers also have a noted side effect…